This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4 Jan 2012

Isotechnika Signs License Agreement with Vifor

Isotechnika has inked a deal with Swiss-based drug maker Vifor to commercialize the company’s lead drug candidate voclosporin for treatment of lupus.

Isotechnika Pharma has signed a global development and commercialization license agreement with Vifor Pharma Ltd., granting Vifor an exclusive license for voclosporin.


The product is used for the treatment of lupus and all proteinuric nephrology indications.


The license is for the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong.


Isotechnika is eligible to receive upfront and milestone payments, as well as royalties on commercial sales. Vifor will also purchase voclosporin capsules from Isotechnika.


Dr. Robert Foste

Related News